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A recently introduced system for antibody detection (ReACT™) con-
sists of affinity columns (AFC) that contain protein A and protein G-
coated agarose.  We compared the ReACT™ system to a conven-
tional tube low-ionic-strength saline antiglobulin test (LISS-AGT).  We
selected 100 LISS-AGT positive samples with clinically important and
benign antibodies of varying strengths and 130 LISS-AGT negative
samples to evaluate by the AFC method.  AFC tests were positive
with all 84 clinically important antibodies, including 36 antibodies
that reacted ≤ 1+ at LISS-AGT (0% falsely negative).  Eleven of 16
(69%) clinically benign antibodies reacted by AFC.  Five samples (2
anti-Sda, 2 anti-I, and 1 inconclusive) were negative by AFC. AFC tests
were negative with all 130 samples that were negative by LISS-AGT
(0% falsely positive).  The AFC method showed results comparable
with results obtained with a conventional tube LISS-AGT for detec-
tion of clinically important antibodies.  Some unwanted, clinically
benign antibodies may not be detected by the AFC method.
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Microcolumns containing agarose coated with pro-
tein A and protein G have been developed for red blood
cell (RBC) antibody detection tests. In contrast to other
microcolumn systems that trap agglutinated RBCs in an
immunologically inert matrix, the ReACT™ (Red Cell
Affinity Column Technology) system (Gamma Biologi-
cals, Houston,TX) depends on the affinity adherence of
IgG-sensitized RBCs to an immunoreactive matrix.
We compared the affinity column (AFC) method to a
conventional tube low-ionic-strength antiglobulin test
(LISS-AGT) for antibody detection.
Materials and Methods
The LISS-AGT was performed using a LISS additive
solution (Ortho-Clinical Diagnostics, Raritan, NJ).
Antibody screening tests consisted of mixing 2 drops of
serum or plasma, 2 drops of LISS, and one drop of 3% to
4% reagent RBCs, incubating for 15 minutes at 37°C,and
then converting to the antiglobulin test using monospe-
cific anti-IgG (Organon-Teknika, Durham, NC).
Agglutination was graded from 0 to 4+. Antibody identi-
fication tests were performed using the LISS method
according to the guidelines in the American Association
of Blood Banks Technical Manual.1 Using results
obtained with the standard tube LISS-AGT, we selected
100 serum or plasma samples with positive antibody
screening tests that, on further testing, contained anti-
bodies of varying reaction strengths and clinical impor-
tance (Table 1), and 130 samples that had negative anti-
body screening tests. These samples were stored at
–80°C until testing was performed by the AFC method.
Table 1. Antibodies selected for evaluation of the affinity column system 
(categorized by LISS antiglobulin test [LISS-AGT] reaction strength 
and clinical importance)
Antibodies LISS-AGT agglutination category
Clinically important No. ≤1+ 2+ to 4+
Rh system 45 15 30
K 20 8 12
MNSs system 8 5 3
Kidd system 4 2 2
Duffy system 3 3 0
Other 4 3 1
Total 84 36 48
Clinically benign No. ≤ 1+ 2+ to 4+
Lewis system 4 4 0
Cold agglutinin 3 3 0
Knops system 2 2 0
Anti-Sda 2 2 0
Inconclusive* 5 5 0
Total 16 16 0
*Antiglobulin reactivity of no apparent specificity; all common clinically 
significant antibodies excluded
The affinity column system (ReACT™) was obtained
from Gamma Biologicals.This method consists of adding
one drop of serum or plasma and  one drop of LISS-sus-
pended (0.8%) RBCs to each column, incubating at 37°C
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for 15 minutes, followed by centrifuging for 3 minutes.
Reactions were read as either positive or negative. A test
that showed RBCs remaining above or in the immunore-
active matrix was considered positive. A test that
showed all of the RBCs at the bottom of the immunore-
active matrix was considered negative.
Results
Antibody screening tests by the AFC method were
performed on a total of 230 samples: 100 with antibod-
ies of varying reaction strengths and clinical importance
and 130 samples that did not contain atypical antibodies.
The results of these tests are summarized in Table 2. All
84 clinically important antibodies, including 36 antibod-
ies that were ≤ 1+,were detected using the AFC method
(0% falsely negative). Eleven of 16 clinically benign anti-
bodies also were detected by the same test. Five of the
16 benign antibodies, anti-Sda (2), anti-I (2), and incon-
clusive (1), were not detected using the AFC method.
The 130 inert samples were nonreactive by the AFC
method (0% falsely positive).
Table 2. Results using the affinity column system for antibody detection
LISS-AGT Antibody Categories
Clinically important Clinically benign
Results ≤ 1+ 2+ to 4+ ≤ 1+ Negative
Affinity 36 48 11 0
column 
positive*
Affinity 0 0 5 130
column 
negative
Total 36 48 16 130
*Affinity column test results were interpreted as either positive or negative
Discussion
Microcolumn systems offer several advantages over
standard test tube methods.2 In particular, reactions in
microcolumns are stable and more reproducible than
the typical agglutination reactions of test tube tech-
niques.2
A microcolumn system containing gel particles (the
gel test) and antiglobulin serum for antibody detection
was developed by Lapierre et al.3 in 1985, and several
studies have demonstrated the utility of this method.2-5
In the gel test, the gel acts as a molecular sieve that sep-
arates agglutinated from unagglutinated RBCs.
In contrast to the gel test system, the microcolumn
system used in the present study contains proteins A and
G covalently coupled to the agarose.6 Proteins A and G
are bacterial proteins that bind specifically to the Fc por-
tion of IgG molecules. Protein A binds to IgG1,IgG2,and
IgG4 subclasses but does not bind to IgG3. Protein G
binds to all four IgG subclasses. Coupling these proteins
to agarose creates an immunoreactive matrix or an affin-
ity column system. RBCs sensitized with IgG antibody
will specifically adhere to the matrix, whereas unsensi-
tized RBCs will pass through the matrix.
In this article, we compared the AFC system to our
standard tube LISS-AGT for antibody detection. The
study was designed to test the affinity column system
with antibodies of varying strength and clinical impor-
tance and with samples that had negative antibody
screening tests by a standard tube LISS-AGT. The AFC sys-
tem reactions were relatively easy to read, and antibod-
ies that reacted only weakly by the LISS-AGT were clear-
ly discernable using the affinity columns. Although
reactions by the affinity column system in our study
were only graded as positive or negative, the strength of
the reactions were consistent with the LISS tube
method. Antibodies that reacted 3+ to 4+ by a LISS-AGT
reacted strongly by the affinity column method with vir-
tually all RBCs remaining above or in the immunoreac-
tive matrix. Alternatively, antibodies that reacted only
weakly by the LISS-AGT method generally reacted only
weakly by the affinity column system, with only a small
portion of the screening cells remaining above or with-
in the matrix. Our results indicated that the AFC system
is comparable with our LISS tube method for the detec-
tion of clinically significant antibodies. The study also
showed that some unwanted or clinically benign anti-
bodies (e.g.,anti-Sda) may not be demonstrable using the
AFC system. This finding is not surprising because many
of the clinically benign antibodies are IgM; the AFC sys-
tem is designed to be specific for IgG alone.6
The AFC system offers the advantages of microcol-
umn system technology and appears to be comparable
in sensitivity and specificity with a standard tube LISS-
AGT for the detection of clinically important antibodies.
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